New Therapies on the Horizon

Alissa J Cooper; Rebecca S Heist

doi:10.1016/j.hoc.2023.02.004

New Therapies on the Horizon

Hematol Oncol Clin North Am. 2023 Jun;37(3):623-658. doi: 10.1016/j.hoc.2023.02.004. Epub 2023 Apr 5.

Authors

Alissa J Cooper¹, Rebecca S Heist²

Affiliations

¹ Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 7B, Boston, MA 02114, USA. Electronic address: acooper@mgh.harvard.edu.
² Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 7B, Boston, MA 02114, USA.

PMID: 37029036
DOI: 10.1016/j.hoc.2023.02.004

Abstract

Although lung cancer treatment has been transformed by the advent of checkpoint inhibitor immunotherapies, there remains a high unmet need for new effective therapies for patients with progressive disease. Novel treatment strategies include combination therapies with currently available programmed death ligand 1 inhibitors, targeting alternative immune checkpoints, and the use of novel immunomodulatory therapies. In addition, antibody-drug conjugates offer great promise as potent management options. As these agents are further tested in clinical trials, we anticipate that more effective therapies for patients with lung cancer are integrated into regular clinical practice.

Keywords: Antibody-drug conjugate; Immune checkpoints; Immunotherapy resistance; Lung cancer; Novel therapies.

Publication types

Review

MeSH terms

Combined Modality Therapy
Humans
Immunotherapy
Lung Neoplasms* / therapy